

**Table S6.** Proportion of patients who discontinued and reasons for discontinuation of first-, second-, and third-line therapy; patients with psoriatic arthritis initiating new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>
First-Line Therapy, N	41	20	33	25
Number (%) Discontinued	7 (17.1)	3 (15.0)	6 (18.2)	7 (28.0)
Reason for Discontinuation, n				
Lack of Effectiveness	5	3	4	3
Patient Choice	1	-	-	1
Insurance/Reimbursement	-	-	2	2
Other	1	-	1	-
Adverse Event	-	1	-	1
Second-Line Therapy, N	63	18	84	27
Number (%) Discontinued	13 (20.6)	8 (44.4)	28 (33.3)	10 (37.0)
Reason for Discontinuation, n				
Lack of Effectiveness	7	3	13	5
Other	3	-	2	1
Patient Choice	1	-	4	1
Insurance/Reimbursement	1	1	3	2
Adverse Event	-	2	4	2
Third-Line Therapy, N	82	19	22	18
Number (%) Discontinued	20 (24.4)	6 (31.6)	8 (36.4)	9 (50.0)
Reason for Discontinuation, n				
Lack of Effectiveness	10	3	4	6
Patient Choice	3	1	-	-
Other	3	-	1	1
Insurance/Reimbursement	3	-	-	-
Adverse Event	2	1	2	2